Is This GlaxoSmithKline's Next Big Blockbuster?

The rheumatoid arthritis market has exploded in recent years, producing some of big pharma's best-selling blockbuster drugs. AbbVie's (NYSE: ABBV  ) Humira hit sales of more than $9 billion to lead the market last year, but competitors from other companies -- such as Johnson & Johnson's (NYSE: JNJ  ) Remicade, which hauled in more than $6 billion last year to rank among the top drugs in the industry -- have thrived in a crowded but lucrative immunology field.

Humira faces a patent expiration soon, however, and competition continues to heat up in this space. GlaxoSmithKline (NYSE: GSK  ) is the latest firm to eye the arthritis market after it agreed to a licensing deal with German biotech firm MorphoSys (NASDAQOTH: MPSYF  ) this week for its developmental immunology therapy MOR103. Glaxo's pipeline is sizable and solid, but will this deal brew another blockbuster for the firm's future? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss what you need to know.

In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2477463, ~/Articles/ArticleHandler.aspx, 9/22/2014 4:49:05 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement